High dose chemotherapy and allogenic peripheral blood stem cell transplantation for multiple myeloma evolving from intra-abdominal plasmacytoma

Chinese Medical Journal (Taipei)

Volumn 65, Issue 11, 2002, Pages 557-560

  Chung, Kun Ming ^a   Chuang, Shih Sung ^b   Hwang, Wei Shou ^a   Lee, Po Shing ^b   Li, Chin Yang ^c  

^a Department of Internal Medicine   (Taiwan)

^b CHI MEI FOUNDATION HOSPITAL   (Taiwan)

^c MAYO CLINIC   (United States)

Author keywords

Allogenic peripheral blood stem cell transplantation; Extramedullary plasmacytoma; Multiple myeloma

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; EPIRUBICIN; MELPHALAN; PREDNISOLONE; PREDNISONE;

ABDOMINAL TUMOR; ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; DIAGNOSTIC ERROR; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIPLE MYELOMA; PLASMACYTOMA; SKIN MANIFESTATION; SKIN SURGERY; T CELL LYMPHOMA; THORAX WALL;

ABDOMINAL NEOPLASMS; ADULT; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MULTIPLE MYELOMA; PLASMACYTOMA; PREDNISOLONE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036874048     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bataille R. Localized plasmacytomas. Clin Haematol 1982; 11:113-22.
2. Dimopoulos MA, Moulopoulous A, Delasalle K, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Hematol Oncol Clin North Am 1992;6:359-69.
3. Wiltshaw E. The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore) 1976;55:217-38.
4. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphapan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42.
5. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barburi T, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalen and prednisolone even in high risk patients. J Chin Oncol 1991;9:444-8.
6. Gharton G, Tura S, Ljungman P, Belanger B, Brandt L, Cavo M, et al. European Cooperative Group for Bone Marrow Transplantation. allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991;325:1267-73.
7. Gharton G, Tura S, Flesch M, Gratwohl A, Gravett P, Lucarelli G, et al. Bone marrow transplantation in multiple myeloma: report from the European Co-operative Group for Bone Marrow Transplantation. Blood 1987;69:1262-4.
8. Reynolds C, Ratanatharathorn, V, Adams P, Braun T, Silver S, Ayash L, et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 2001;27:801-7.
9. Gahrton G, Tura S, Ljungman P, Blade J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13: 1312.
10. Cavo M, Bandini G, Benni M, Gozzetti A, Ronconi S, Rosti G, et al. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant 1998;22:27-32.
11. Fu YS, Perzin KH. Nonepithelial tumors of the nasal cavity, paranasal sinuses and nasopharynx: a clinicopathologic study. IX. Plasmacytomas. Cancer 1978;42:2399-406.
12. Frizzera G, Wu CD, Inghirami G. The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasmas: an update. Am J Clin Pathol 1999;111 (suppl 1):13-39.